About Us
The 9th Ace Drug Discovery Summit USA 2027 is a premier scientific forum uniting global researchers, biotech leaders, and pharma innovators to explore the latest advancements transforming drug discovery. This two-day summit features cutting-edge sessions on AI-driven drug design, quantum computing in simulation, targeted protein degradation, RNA therapeutics, and sustainable medicinal chemistry. Key discussions will highlight CAR-T cell therapies, immunotherapy combinations, bioinformatics, and nanomedicine, reflecting the evolving landscape of pharmaceutical R&D. Attendees will gain actionable insights into emerging technologies, fragment-based drug design, and AI-powered screening, with a strong focus on unmet medical needs and ethical considerations. With interactive panel discussions, expert-led presentations, and exclusive business meetings, the summit fosters meaningful collaboration and knowledge exchange across the drug development spectrum. Join us to stay at the forefront of innovation and reshape the future of drug discovery and therapeutic development.
Why Attend
Solutions at ADDS
🔷Antibody Engineering
🔷Biochemistry
🔷Bio-informatics
🔷ADMUPI (Toxicology)
🔷Biomarker Validation
🔷Combinatorial Chemistry
🔷Covering Biological studies
🔷Data Management
   Technology
🔷Digital Imaging Technology
🔷DNA & RNA Analysis
🔷DNA Sequencing Services
🔷Drug Discovery Technology
   Platforms
🔷Preclinical
🔷Principal Scientists
🔷Regulatory Affairs
🔷Research & Development
🔷Transgenesis Services
🔷Genomics
🔷High Throughput Screening
🔷Licensing
🔷lmaging/biomarker
🔷Imaging Tools
Who Will Attend
The 9th Ace Drug Discovery Summit USA 2027 is a premier scientific forum uniting global researchers, biotech leaders, and pharma innovators to explore the latest advancements transforming drug discovery.
🔷CEO
🔷CSO
🔷Director Discovery Alliances
🔷Head of DMPK
🔷Head of Drug Design
🔷Head of Molecula Toxicology
🔷VP Target Discovery & Assessment
🔷Head of R&D Licensing
🔷Principal Scientist
🔷Director of Discovery Strategy Portfolio
🔷Director of Screening & Compound Profiling
🔷Executive Director Chemistry
🔷Head Pharmacology & Toxicology
🔷Drug Discovery R&D Executives
Speakers Panel 2026
Hajnalka Hartl
Head of Chemistry | Orogen Therapeutics
Philip M Arlen
CEO | Precision Biologics
Rick Ewing
VP, Head of Chemistry | Rapafusyn Pharmaceuticals
Humberto Vega-Mercado
President and CEO |
HMV Food and Pharma Consulting, LLC
Igor Nasonkin
CEO |
Phythera Therapeutics
Xin Zhang
Sr. Director, Computational Chemistry | Cellarity
Chester Yuan
CSO |
Sungening Biosciences
Michael Liebman
Managing Director |
IPQ Analytics/WOVEN
Adwitiya Kar
Former Senior Scientist |
Immunitas Therapeutics
Tyler Umansky
Head of Platform and Machine Learning |
Model Medicines
Shicheng Guo
Senior Director |
Arrowhead Pharmaceuticals
Julia Coronella
Former Vice President of Immuno-oncology |
Poseida Therapeutics, Inc.
Bo Chen
Associate Director, Drug Discovery |
Arrowhead Pharmaceuticals
Tony Yaksh
Professor |
UC San Diego
Vivek Gupta
Associate Professor |
St. John’s University
Jitendra Kumar
Lead Scientist: Chemistry and Process Development |
Entos Pharmaceuticals US, Inc.
Kinkini Roy
Principal, Director of Research |
Stealth Mode Biotech
Amy He
Research Scientist |
Topos Bio
Rose Yu
Associate Professor |
UC San Diego
Shane Lewin
CEO |
Clockwork Bio
Milad Rouhimoghadam
Senior Scientist |
AbbVie
MaryLena Bleile
Statistician | Independent
Sara Dochnal
Postdoctoral Fellow |
UC San Diego
Ruben Abagyan
Professor |
University of California, San Diego
David Gonzalez
Professor |
UC San Diego
Our Sponsors
Attendee Breakdown
Attendee Demographics
Conference Themes
05th May
Next-Generation Drug Discovery and Molecular Design
Biomarker Discovery for Precision Oncology
Next Generation Target Discovery through AI
Translational Research in the Era of Precision Medicine
Targeting Neurological Diseases through Gene Therapy Approaches
The Evolution of in vitro models
Transforming RNA Target Identification with Bioinformatics
06th May
Computational Medicinal Chemistry for Lead Optimization
Novel approaches for cell & gene therapy
Sustainable Practices in Medicinal Chemistry
In-silico Drug Design
Advancing ADC Development Through AI-Based PBPK Modeling
How successful are AI/ML Approaches in Drug Development
Next Generation Target Discovery through AI
Our Partners
Media Partners
Marriott International begins as an A&W Root Beer franchise in Washington, D.C., in May 1927, with the same core values that guide the company today. Founders J. Willard and Alice Sheets Marriott get their business started by quenching people’s thirst during the hot, muggy summers in Washington, D.C., before serving food and becoming The Hot Shoppes, and entering other lines of business. Heralding in a new era in 2016, Marriott International acquires Starwood Hotels & Resorts Worldwide creating the world’s largest hotel company. There is a celebration in New York City’s Time Square.